Skip to content
For research purposes only — not for human consumption. For laboratory and educational reference.
Double Agonist
Metabolic

Double Agonist

Tirzepatide

Tirzepatide is a 39-amino-acid synthetic peptide and a dual agonist of the GIP and GLP-1 receptors, originally developed by Eli Lilly under the designation LY3298176. It has been studied extensively in metabolic research for its relationship to glucose regulation, adiposity, insulin signaling, and food intake behavior across both preclinical and human trial settings.

Quantity

Mon, Jun 8 - Sun, Jun 14

Free shipment protection

Overnight shipping available

We accept
Apple Pay
Visa
Mastercard
2023788-19-2
CAS
4813.524 g/mol
Molecular weight
3mL
Vial

What is Tirzepatide?

Metabolic · 20mg, 40mg · 3mL

Tirzepatide is a 39-amino-acid synthetic peptide and a dual agonist of the GIP and GLP-1 receptors, originally developed by Eli Lilly under the designation LY3298176. It has been studied extensively in metabolic research for its relationship to glucose regulation, adiposity, insulin signaling, and food intake behavior across both preclinical and human trial settings. Its dual-incretin architecture marked a notable shift from earlier single-pathway GLP-1 compounds and established the foundation for a broader class of multi-agonist metabolic peptides. Lyophilized powder, 3mL vial. Sold at 20mg and 40mg per vial. For research use only.

FDA-approved as Mounjaro/Zepbound. Some retailers cite 4858.5 (acetate salt).

Compound Information

Technical specifications

Molecular Profile

What Is Double Agonist?

Type Peptide
CAS Number 2023788-19-2
Molecular Weight 4813.524 g/mol
Formula C225H348N48O68
PubChem Database
Storage Requirements

Stability Information

  • Lyophilized
  • Protect from light
  • For research use only
  • Lyophilized
    -20°C 24 months (unopened)
  • Reconstituted
    2–8°C Up to 30 days
  • Working solution
    2–8°C Use within 7 days

Product specifications

Technical details

Technical specifications
CAS number
2023788-19-2
Molecular formula
C225H348N48O68
Molecular weight
4813.524 g/mol g/mol
Type
Peptide
Vial size
3mL
Molecular weight
4813.524 g/mol — Registry verified

Storage & Handling

Storage conditions for unopened vials

LYOPHILIZED
-20°C

Long-term storage. Protect from moisture and light.

RECONSTITUTED
2–8°C

Refrigerate after reconstitution. Do not freeze reconstituted solution unless validated for your protocol.

SHIPPING
Ambient

Lyophilized peptides ship at ambient temperature under normal conditions.

WARNINGS
  • For research use only — not for human or veterinary consumption.
  • Handle with appropriate PPE in a controlled laboratory environment.
  • Confirm form, salt, and concentration against your supplier CoA before use.

Sources & References

Peer-reviewed research

Database PubChem CID 156588324 View Source
Database DB15171 View Source

Tirzepatide is a 39-amino-acid synthetic peptide and a dual agonist of the GIP and GLP-1 receptors, originally developed by Eli Lilly under the designation LY3298176. It has been studied extensively in metabolic research for its relationship to glucose regulation, adiposity, insulin signaling, and food intake behavior across both preclinical and human trial settings. Its dual-incretin architecture marked a notable shift from earlier single-pathway GLP-1 compounds and established the foundation for a broader class of multi-agonist metabolic peptides. Lyophilized powder, 3mL vial. Sold at 20mg and 40mg per vial. For research use only.

You may also like these products

All the research peptides you need, with the peace of mind.

Shop Now

Research updates from retaUp

Subscribe for catalog updates, new research compounds, and quality documentation news.

For researchers and labs. No spam, unsubscribe anytime.